Applicability of biomarkers in the early diagnosis of prostate cancer

Expert Review of Molecular Diagnostics
Daphne HesselsJ Alfred Witjes

Abstract

Early diagnosis of prostate cancer can increase the curative success rate for this disease. Although serum prostate-specific antigen measurement is regarded as the best conventional tumor marker available, there is little doubt that it has great limitations. The threshold above which biopsies are indicated has now decreased to a serum prostate-specific antigen value of 3 ng/ml, which results in a negative biopsy rate of 70-80%. This can readily be explained by the fact that prostate-specific antigen is not specific for prostate cancer. Clinicians need more sensitive tools to help diagnose prostate cancer and monitor progression of the disease. Molecular oncology is playing an increasing role in the fields of diagnosis and therapy for prostate cancer and has already been instrumental in elucidating many of the basic mechanisms underlying the development and progression of this disease. The identification of new prostate cancer-specific genes, such as DD3PCA3, would represent a considerable advance in the improvement of diagnostic tests for prostate cancer. This could subsequently lead to a reduction of the number of unnecessary biopsies.

References

Jan 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·O M JensenH Renard
Oct 8, 1987·The New England Journal of Medicine·T A StameyE Redwine
Oct 18, 1995·JAMA : the Journal of the American Medical Association·W J CatalonaR B Nadler
Aug 1, 1995·Nature Medicine·K R MonroeB E Henderson
Aug 1, 1995·European Journal of Biochemistry·W SchmitzE Conzelmann
Nov 22, 1994·Proceedings of the National Academy of Sciences of the United States of America·W H LeeW G Nelson
Jan 6, 1997·International Journal of Cancer. Journal International Du Cancer·W HenkeS A Loening
Mar 17, 1999·Proceedings of the National Academy of Sciences of the United States of America·P S NelsonK Wang
Aug 25, 2001·Cancer Causes & Control : CCC·D S MichaudE Giovannucci
Nov 16, 2001·Annals of the New York Academy of Sciences·C GoesslK Miller
Feb 28, 2002·Lancet·Emanuel F PetricoinLance A Liotta
Mar 21, 2002·Expert Review of Molecular Diagnostics·E P Diamandis, G M Yousef
Apr 3, 2002·JAMA : the Journal of the American Medical Association·Mark A RubinArul M Chinnaiyan
May 29, 2002·Urology·Stephen D MikolajczykHarry G Rittenhouse
Jun 21, 2002·European Urology·Carsten GoesslKurt Miller
Aug 3, 2002·Nature Reviews. Cancer·María A Blasco
Oct 3, 2002·Oncogene·Limin LiuGerd P Pfeifer
Feb 7, 2003·Trends in Biotechnology·Emanuel F Petricoin, Lance A Liotta
Apr 3, 2003·Nature Reviews. Cancer·Ruth EtzioniLeland Hartwell
May 2, 2003·Annals of the New York Academy of Sciences·Shuanfang LiJ Carl Barrett
Jun 7, 2003·Endocrine-related Cancer·J SimardS V Tavtigian
Jun 20, 2003·European Urology·Daphne HesselsJack A Schalken
Jul 11, 2003·The Journal of Urology·Lionel L BañezShiv Srivastava
Jul 17, 2003·The Keio Journal of Medicine·Stephen D Mikolajczyk, Harry G Rittenhouse
Jul 25, 2003·Expert Review of Molecular Diagnostics·Chandan Kumar-SinhaArul M Chinnaiyan
Dec 11, 2003·The Journal of Urology·Carsten StephanEleftherios P Diamandis
Apr 1, 2004·Clinical Chemistry·Stephen D MikolajczykHarry G Rittenhouse

❮ Previous
Next ❯

Citations

Sep 7, 2014·BMC Cancer·Nataša VasiljevićAttila T Lorincz
Jul 22, 2008·Clinical Biochemistry·Adriana F NevesLuiz R Goulart
Jun 29, 2013·Seminars in Oncology·Tapan BhavsarRuth Birbe
Feb 17, 2007·Cancer Letters·Mark A ReynoldsHarry Rittenhouse
Nov 18, 2014·Biomarkers in Medicine·Nataša VasiljevićAttila T Lorincz
Dec 9, 2014·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Alena BurdovaZdenek Kolar
Oct 26, 2007·International Journal of Cancer. Journal International Du Cancer·Morgan RouprêtFreddie C Hamdy
May 9, 2009·Nature Reviews. Urology·Daphne Hessels, Jack A Schalken
Dec 20, 2005·BJU International·Jack A Schalken
Apr 19, 2007·The Prostate·Martijn P M Q van GilsJack A Schalken
Mar 22, 2014·Expert Review of Molecular Diagnostics·Attila T Lorincz
Jul 22, 2010·Expert Review of Anticancer Therapy·Md Imtaiyaz HassanFaizan Ahmad
Sep 16, 2017·Frontiers in Physiology·Jiazeng SunJuan Shi
Mar 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Morgan RouprêtOlivier Cussenot
Sep 6, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daphne HesselsJack A Schalken
Aug 20, 2020·ACS Sensors·Chunyu JiZhili Peng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cadherins and Catenins

Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells: alpha-catenin can bind to β-catenin and can also bind actin. β-catenin binds the cytoplasmic domain of some cadherins. Discover the latest research on cadherins and catenins here.

Adherens Junctions

An adherens junction is defined as a cell junction whose cytoplasmic face is linked to the actin cytoskeleton. They can appear as bands encircling the cell (zonula adherens) or as spots of attachment to the extracellular matrix (adhesion plaques). Adherens junctions uniquely disassemble in uterine epithelial cells to allow the blastocyst to penetrate between epithelial cells. Discover the latest research on adherens junctions here.

Related Papers

JAMA : the Journal of the American Medical Association
Mark A RubinArul M Chinnaiyan
Expert Review of Molecular Diagnostics
Chandan Kumar-SinhaArul M Chinnaiyan
© 2022 Meta ULC. All rights reserved